Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$17.99 +0.9%	$18.15	$16.10 ▼ $42.47	$2.29B	0.67	2.35 million shs	891,120 shs
ARWR Arrowhead Pharmaceuticals	$16.78 -0.7%	$15.45	$9.57 ▼ $30.41	$2.32B	0.93	1.55 million shs	800,545 shs
SAGE Sage Therapeutics	$9.20 +1.3%	$7.53	$4.62 ▼ $13.47	$576.11M	0.29	1.30 million shs	3.01 million shs
TWST Twist Bioscience	$38.11 +1.1%	$33.49	$27.12 ▼ $60.90	$2.29B	2.41	964,558 shs	445,333 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+3.18%	-2.84%	-9.94%	-49.21%
ARWR Arrowhead Pharmaceuticals	0.00%	+4.35%	+0.24%	+57.12%	-33.07%
SAGE Sage Therapeutics	0.00%	+0.49%	+40.60%	+34.04%	-13.42%
TWST Twist Bioscience	0.00%	+6.07%	+25.20%	+5.31%	-20.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.5197 of 5 stars	4.3	1.0	4.4	2.5	2.5	0.6
ARWR Arrowhead Pharmaceuticals	3.9263 of 5 stars	3.4	2.0	3.4	2.7	2.5	0.0
SAGE Sage Therapeutics	3.2188 of 5 stars	2.0	2.0	4.0	2.3	1.7	0.6
TWST Twist Bioscience	4.4074 of 5 stars	4.4	2.0	4.4	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.79	121.24% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.51% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.85% Downside
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	32.25% Upside

Current Analyst Ratings Breakdown

Latest SAGE, TWST, ARWR, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.89	N/A	N/A	$1.84 per share	9.77
ARWR Arrowhead Pharmaceuticals	$3.55M	652.77	N/A	N/A	$1.54 per share	10.90
SAGE Sage Therapeutics	$41.24M	13.96	N/A	N/A	$7.60 per share	1.21
TWST Twist Bioscience	$312.97M	7.30	N/A	N/A	$8.07 per share	4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	19.75	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/1/2025 (Estimated)

Latest SAGE, TWST, ARWR, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
SAGE Sage Therapeutics	N/A	9.13	9.13
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
ARWR Arrowhead Pharmaceuticals	62.61%
SAGE Sage Therapeutics	99.22%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
ARWR Arrowhead Pharmaceuticals	4.30%
SAGE Sage Therapeutics	5.50%
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

SAGE, TWST, ARWR, and APLS Headlines

Recent News About These Companies

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 2 at 4:09 AM | americanbankingnews.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Brokerages

July 2 at 4:03 AM | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by Sumitomo Mitsui Trust Group Inc.

June 30, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells $10,441.92 in Stock

June 25, 2025 | insidertrades.com

Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells 292 Shares of Stock

June 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,678 Shares

June 24, 2025 | marketbeat.com

Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions

June 23, 2025 | insidermonkey.com

SG Americas Securities LLC Acquires New Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

June 19, 2025 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Trading 7.2% Higher - Time to Buy?

June 18, 2025 | marketbeat.com

Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation

June 16, 2025 | finance.yahoo.com

Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

NBC Securities Inc. Takes $337,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

June 7, 2025 | marketbeat.com

Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Analysts

June 7, 2025 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Shares Gap Up - Here's What Happened

June 6, 2025 | marketbeat.com

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner Sells 839 Shares

May 29, 2025 | insidertrades.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 531 Shares

May 24, 2025 | insidertrades.com

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

May 15, 2025 | 01net.it0

Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

May 9, 2025 | msn.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 689 Shares

May 8, 2025 | insidertrades.com

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025 | businesswire.com

TWIST BIOSCIENCE Earnings Results: $TWST Reports Quarterly Earnings

May 7, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAGE, TWST, ARWR, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$17.98 +0.17 (+0.93%)

Closing price 07/3/2025 03:48 PM Eastern

Extended Trading

$17.93 -0.05 (-0.31%)

As of 07/3/2025 04:48 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.78 -0.12 (-0.71%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$16.78 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Sage Therapeutics NASDAQ:SAGE

$9.20 +0.12 (+1.27%)

Closing price 07/3/2025 02:52 PM Eastern

Extended Trading

$9.20 0.00 (0.00%)

As of 07/3/2025 04:28 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Twist Bioscience NASDAQ:TWST

$38.11 +0.43 (+1.14%)

Closing price 07/3/2025 03:40 PM Eastern

Extended Trading

$38.52 +0.41 (+1.09%)

As of 07/3/2025 04:20 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time